Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre-quit and post-quit periods
- PMID: 30370685
- DOI: 10.1111/add.14483
Progressive nicotine patch dosing prior to quitting smoking: feasibility, safety and effects during the pre-quit and post-quit periods
Abstract
Background and aims: Nicotine replacement therapy (NRT) may be more effective in aiding smoking cessation if higher doses of nicotine from it can be tolerated. We examined the responses to, and 4-week abstinence rates observed, when titrating the dose of transdermal nicotine patch up to 84 mg/day over 4 weeks prior to a target quit date and titrating down again over 4 weeks afterwards.
Design: Clinical cohort study.
Setting: Tobacco dependence clinic, Mar del Plata, Argentina.
Participants: Fifty smokers seeking help with stopping smoking.
Intervention: Participants started on one 21-mg/24-hour patch 4 weeks prior to their target quit day (TQD). The dose was increased weekly by adding a 21-mg patch unless participants reported adverse effects and/or did not wish to increase the dose. The dose was reduced by 21 mg/day each week from 1 week post-TQD, until it reverted to the standard dose (21 mg/day) at 4 weeks post-TQD. Participants received weekly behavioural support and could also use oral NRT from the TQD. Participants were advised to smoke ad libitum during the pre-quit period.
Measurements: Proportion of participants progressing through each stage of dosing, adherence, adverse effects, changes in cigarette consumption, smoke intake and enjoyment of smoking during the pre-quit period; withdrawal symptoms; carbon monoxide-validated abstinence during 4 weeks post-TQD.
Findings: Of the 50 participants, 72.0% (n = 36) progressed to the 84-mg nicotine dose and 94.0% (n = 47) completed the trial. Adverse effects consisted primarily of nausea and were mild and well tolerated. Cigarette consumption, smoke intake and enjoyment of smoking declined significantly during the pre-quit period. Forty-one (82%) participants achieved 4 weeks validated abstinence. Abstainers experienced no detectable cigarette withdrawal symptoms.
Conclusions: Most smokers seeking help with stopping appear to be able to tolerate doses of transdermal nicotine patch up to 84 mg/day during a 4-week pre-quit up-titration period with minimal side effects.
Keywords: Nicotine; nicotine replacement treatment; nictoine transdermal patch; pre-loading; smoking cessation; tobacco dependence.
© 2018 Society for the Study of Addiction.
Similar articles
-
Mediators of the effect of nicotine pre-treatment on quitting smoking.Addiction. 2018 Dec;113(12):2280-2289. doi: 10.1111/add.14401. Epub 2018 Sep 16. Addiction. 2018. PMID: 30066385 Clinical Trial.
-
Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.Cochrane Database Syst Rev. 2019 Apr 18;4(4):CD013308. doi: 10.1002/14651858.CD013308. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2023 Jun 19;6:CD013308. doi: 10.1002/14651858.CD013308.pub2. PMID: 30997928 Free PMC article. Updated.
-
E-cigarettes compared with nicotine replacement therapy within the UK Stop Smoking Services: the TEC RCT.Health Technol Assess. 2019 Aug;23(43):1-82. doi: 10.3310/hta23430. Health Technol Assess. 2019. PMID: 31434605 Free PMC article. Clinical Trial.
-
Comparative effects of varenicline or combination nicotine replacement therapy versus patch monotherapy on candidate mediators of early abstinence in a smoking cessation attempt.Addiction. 2021 Apr;116(4):926-935. doi: 10.1111/add.15248. Epub 2020 Oct 1. Addiction. 2021. PMID: 32888230 Free PMC article. Clinical Trial.
-
Smoking reduction interventions for smoking cessation.Cochrane Database Syst Rev. 2019 Sep 30;9(9):CD013183. doi: 10.1002/14651858.CD013183.pub2. Cochrane Database Syst Rev. 2019. PMID: 31565800 Free PMC article.
Cited by
-
Characterizing nicotine withdrawal in smokers experiencing homelessness.J Subst Abuse Treat. 2022 Jul;138:108748. doi: 10.1016/j.jsat.2022.108748. Epub 2022 Feb 19. J Subst Abuse Treat. 2022. PMID: 35241351 Free PMC article. Clinical Trial.
-
TOBACCO USE DISORDER AND DUAL DISORDERS Joint statement by the Spanish Psychiatry Society and the Spanish Dual Disorders Society.Actas Esp Psiquiatr. 2022 Jun;50(Supplement):77-138. Epub 2022 Jun 1. Actas Esp Psiquiatr. 2022. PMID: 35731182 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical